Result:Weak· Market: Flat#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 0.00 | ||
| Total Income | 0.00 | 100.0% | |
| Expenditure | 0.06 | 75.2% | 36.2% |
| PBT | -0.06 | 75.0% | 36.2% |
| Net Profit | -0.06 | 75.0% | 36.2% |
| OPM | — | ||
| NPM | — | ||
| EPS | 0.14 | 74.5% |
No revenue for a second straight year and a continued net loss, though the loss narrowed 36% YoY off a near-zero base, leaves this below-par for pharma with no core business to assess.
Informational and educational content only. Not investment advice.